Cargando…

Tamsulosin and Solifenacin in the Treatment of Benign Prostatic Hyperplasia in combination with overactive bladder

OBJECTIVE: To analyze the clinical effect of tamsulosin and Solifenacin in the treatment of benign prostatic hyperplasia in combination with overactive bladder and its safety. Another objective was to investigate the clinical effect and safety of mega dose of tamsulosin in the treatment of benign pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Hui, Chang, Yanhua, Liang, Hui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Professional Medical Publications 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648978/ https://www.ncbi.nlm.nih.gov/pubmed/29067079 http://dx.doi.org/10.12669/pjms.334.12757

Ejemplares similares

Impact of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Treatment with Tamsulosin and Solifenacin Combination Therapy on Erectile Function
por: Seo, Deok Ha, et al.
Publicado: (2011)

The Add-On Effect of Solifenacin for Patients with Remaining Overactive Bladder after Treatment with Tamsulosin for Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction
por: Masumori, Naoya, et al.
Publicado: (2010)

Solifenacin/tamsulosin fixed-dose combination therapy to treat lower urinary tract symptoms in patients with benign prostatic hyperplasia
por: Dimitropoulos, Konstantinos, et al.
Publicado: (2015)

Comparison of solifenacin and fesoterodine in treatment of overactive bladder
por: Ercan, Önder, et al.
Publicado: (2015)

Pharmacokinetics of solifenacin in pediatric populations with overactive bladder or neurogenic detrusor overactivity
por: Tannenbaum, Stacey, et al.
Publicado: (2020)

The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: A systematic review and meta-analysis
por: Su, Shunye, et al.
Publicado: (2020)

Effects of Tamsulosin, Solifenacin, and Combination Therapy for the Treatment of Ureteral Stent Related Discomforts
por: Lim, Kyoung Taek, et al.
Publicado: (2011)

Effects of Tamsulosin on Premature Ejaculation in Men with Benign Prostatic Hyperplasia
por: Choi, Jae Hwi, et al.
Publicado: (2014)

Cost-effectiveness of a fixed-dose combination of solifenacin and oral controlled adsorption system formulation of tamsulosin in men with lower urinary tract symptoms associated with benign prostatic hyperplasia
por: Nazir, Jameel, et al.
Publicado: (2015)

A Comparative Study of Solifenacin, Mirabegron, and Their Combination as Bladder Relaxants in the Management of Overactive Bladder
por: Kumar, Shailendra, et al.
Publicado: (2023)

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)

Efficacy of combination therapy with tamsulosin and zolpidem on nocturia in patients with benign prostatic hyperplasia
por: Miwa, Kousei, et al.
Publicado: (2011)

Evaluation of intermittent tamsulosin in treating symptomatic patients with benign prostatic hyperplasia
por: Soliman, Mohamed G., et al.
Publicado: (2023)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
por: Zhou, Zhongbao, et al.
Publicado: (2019)

Solifenacin significantly improves all symptoms of overactive bladder syndrome
por: CHAPPLE, C R, et al.
Publicado: (2006)

Short-term Effect of Tamsulosin and Finasteride Monotherapy and their Combination on Nigerian Men with Benign Prostatic Hyperplasia
por: Odusanya, Benjamin O, et al.
Publicado: (2017)

Effect of Improvement in Lower Urinary Tract Symptoms on Sexual Function in Men: Tamsulosin Monotherapy vs. Combination Therapy of Tamsulosin and Solifenacin
por: Ko, Kyungtae, et al.
Publicado: (2014)

Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
por: Xu, Yankai, et al.
Publicado: (2017)

Solifenacin in Multiple Sclerosis Patients with Overactive Bladder: A Prospective Study
por: van Rey, Farida, et al.
Publicado: (2011)

A 52‐week multicenter randomized controlled study of the efficacy and safety of add‐on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study)
por: Yamanishi, Tomonori, et al.
Publicado: (2018)

Clinical Factors Associated With Dose Escalation of Solifenacin for the Treatment of Overactive Bladder in Real Life Practice
por: Chun, Ji-Youn, et al.
Publicado: (2014)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
por: Hakimi, Zalmai, et al.
Publicado: (2018)

Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
por: Chung, Jae-Wook, et al.
Publicado: (2011)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
por: Barkin, Jack
Publicado: (2011)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
por: Djavan, Bob, et al.
Publicado: (2011)

Improvement of the symptoms of lower urinary tract and sexual dysfunction with tadalafil and solifenacin after the treatment of benign prostatic hyperplasia with dutasteride
por: Kosilov, Kirill V., et al.
Publicado: (2020)

Comparative evaluation of naftopidil and tamsulosin in the treatment of patients with lower urinary tract symptoms with benign prostatic hyperplasia
por: Griwan, Mahavir Singh, et al.
Publicado: (2014)

Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose?
por: Lee, Cheng-Ling, et al.
Publicado: (2023)

Evaluation of silodosin in comparison to tamsulosin in benign prostatic hyperplasia: A randomized controlled trial
por: Pande, Satabdi, et al.
Publicado: (2014)

Influence of Daytime or Nighttime Dosing with Solifenacin for Overactive Bladder with Nocturia: Impact on Nocturia and Sleep Quality
por: Kwon, Taekmin, et al.
Publicado: (2017)

Efficacy and tolerability of mirabegron compared with solifenacin for children with idiopathic overactive bladder: A preliminary study
por: Kim, Seong Cheol, et al.
Publicado: (2021)

Transcutaneous electrical nerve stimulation and solifenacin succinate versus solifenacin succinate alone for treatment of overactive bladder syndrome: A double-blind randomized controlled study
por: Zhang, Yumeng, et al.
Publicado: (2021)

Combination therapy with curcumin plus tamsulosin and finasteride in the treatment of men with benign prostatic hyperplasia: a single center, randomized control study
por: Qiao, Jing, et al.
Publicado: (2021)

Pooled solifenacin overactive bladder trial data: Creation, validation and analysis of an integrated database
por: Chapple, Christopher R., et al.
Publicado: (2016)

Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis
por: Majdinasab, Nastaran, et al.
Publicado: (2023)

Comparison of Serenoa repens With Tamsulosin in the Treatment of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis
por: Cai, Tong, et al.
Publicado: (2020)

Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker Therapy
por: Cai, Tong, et al.
Publicado: (2020)

Beneficial Effect of Increasing the Dose of Tamsulosin to 0.4 mg in Japanese Patients with Benign Prostatic Hyperplasia
por: Hirose, Yasuhiko, et al.
Publicado: (2011)

Additive effect of oral LDD175 to tamsulosin and finasteride in a benign prostate hyperplasia rat model
por: Choi, Bo Ram, et al.
Publicado: (2018)

Dutasteride plus Tamsulosin fixed-dose combination first-line therapy versus Tamsulosin Monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting
por: Geitona, Maria, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ood8i93loikd4a0jl45mr2tmfa